Regeneron brings patent infringement proceedings against Samsung Biologics and Samsung Boepis over Eylea® (aflibercept)

Jan 16, 2023

Business Korea has reported that Regeneron has filed patent infringement and prevention claims against Samsung Biologics and its subsidiary Samsung Boepis relating to Eylea® (aflibercept).  Regeneron claims that the Samsung Bioepis’ aflibercept (biosimilar to Eylea®) infringes Regeneron’s Korean patents.   

This comes only a few days after Samsung Bioepis filed a petition for inter partes review of Regeneron’s US10,130,681, relating to Eylea® in the US.    

Print Page Mail Article